N-acetylcysteine in Bulimia Nervosa

Lindner Center of HOPE

Status and phase: Terminated; Phase 3; Phase 2

Conditions: NAC

Treatments: Drug: N-acetylcysteine NAC

Study type: Interventional

Funder types: Other

Identifiers

NCT01131572

IRB19223, 09-09-18-01

Details and patient eligibility

About

This study tests NAC in the treatment of Bulimia Nervosa.

Enrollment: 11 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Bulimia Nervosa
• 18-65 years of age

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

11 participants in 1 patient group

N-acetylcysteine

Other group

Description:

open label treatment. Each subject receives N-acetylcysteine.

Treatment:

Drug: N-acetylcysteine NAC